Inside the research
Medpace Holdings, Inc.
MEDP Research profile · latest available data
Price overview
$618.88
▼ -1.71 (-0.3%)
| 52w hi | $630.19 |
|---|---|
| 52w lo | $393.42 |
| Vol | 229.10K |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.38
| Short | +0.22 |
|---|---|
| Medium | +0.50 |
| Long | +0.48 |
computed 2026-09-27
Key fundamentals
Medpace Holdings, Inc.
Healthcare · Diagnostics & Research
| Market cap | $17.27B |
|---|---|
| Enterprise value | $16.92B |
| Trailing P/E | 36.36x |
| Forward P/E | 32.05x |
| EV / EBITDA | 27.68x |
| P / S (ttm) | 6.21x |
| Profit margin | 17.7% |
| Return on equity | 162.2% |
| Revenue growth | +17.2% |
| Earnings growth | +37.1% |
| Debt / equity | 33.22 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.30 | |
| Sector | +0.08 | |
| Technical | +0.20 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Risk Metrics
| Beta vs SPX | 0.99 |
|---|---|
| Corr SPX | 0.28 |
| Annual vol | 57.1% |
| Annual ret | +40.9% |
| Sharpe | 0.72 |
| Max DD | -36.6% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $442.83 |
|---|---|
| High / Low | $495.00 / $329.00 |
| Median | $456.00 |
| Analysts | 12 |
| Strong Buy | 1 | |
|---|---|---|
| Buy | 3 | |
| Hold | 8 | |
| Sell | 0 | |
| Strong Sell | 1 |
Recent rating actions
| 2026-04-24 | RBC Capital | → Outperform |
| 2026-04-24 | BMO Capital | → Market Perform |
| 2026-04-24 | Barclays | → Equal-Weight |
| 2026-04-24 | Baird | → Outperform |
| 2026-03-06 | Barclays | → Equal-Weight |
| 2026-03-03 | RBC Capital | → Outperform |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-22 | Earnings Release, Exhibits | read |
| 2026-06-04 | Officer / Director Change | read |
| 2026-05-19 | Bylaws Amendment, Shareholder Vote… | read |
| 2026-04-22 | Earnings Release, Officer / Director Change… | read |
| 2026-02-09 | Earnings Release, Exhibits | read |
| 2025-10-22 | Earnings Release, Exhibits | read |
| 2025-07-21 | Material Agreement, Earnings Release… | read |
| 2025-05-16 | Officer / Director Change, Shareholder Vote… | read |
| 2025-04-21 | Material Agreement, Earnings Release… | read |
| 2025-03-31 | Material Agreement, Exhibits | read |
| 2025-02-10 | Earnings Release, Other Material Event… | read |
| 2024-10-21 | Earnings Release, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-11 | McCarthy Cornelius P. III | Sell | 1.14K | $690.12K | |
| 2026-08-11 | Troendle August J. | President & CEO | Sell | 17.61K | $10.66M |
| 2026-08-10 | Troendle August J. | President & CEO | Sell | 5.53K | $3.33M |
| 2026-08-07 | McCarthy Cornelius P. III | Option exercise | 3.86K | $325.46K | |
| 2026-08-07 | McCarthy Cornelius P. III | Sell | 795 | $465.13K | |
| 2026-07-28 | Troendle August J. | President & CEO | Sell | 3.51K | $2.11M |
| 2026-07-28 | BURWIG SUSAN E | Exec. VP, Operations | Sell | 7.50K | $4.50M |
| 2026-07-27 | Troendle August J. | President & CEO | Sell | 3.73K | $2.24M |
| 2026-06-30 | McCarthy Cornelius P. III | Option exercise | 28 | — | |
| 2026-06-30 | Kraft Robert O. | Option exercise | 33 | — |
Flow & Concentration
| Insider 180d net | -$31.34M |
|---|---|
| Insider buys / sells | 0 / 8 |
| Insider bias | Sellers |
| 13F holders | 9 |
| Top-5 share | 97.7% |
| HHI | 3,016 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| AQR Capital Management | $677.31M | 1.28M |
| State Street Corp | $376.48M | 710.89K |
| Renaissance Technologies | $220.09M | 415.59K |
| Capital Research / Capital World | $160.96M | 303.93K |
| Fidelity / FMR LLC | $28.70M | 54.20K |
| Citadel Advisors | $23.83M | 45.00K |
| Bridgewater Associates | $8.26M | 15.61K |
| T. Rowe Price Group | $1.10M | 2.07M |
| Millennium Management | $529.59K | 1.00K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2016–2025 · 10 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $1.89B | +18.1% | |
| Operating income | $446.87M | +48.6% | |
| Net income | $451.12M | +61.9% | |
| Cash from ops | $433.37M | +15.7% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $620.60 | $620.60 | $608.11 | $618.88 | 229.10K |
| Sep 24 | $612.30 | $626.83 | $610.79 | $620.59 | 308.80K |
| Sep 23 | $630.06 | $637.65 | $614.18 | $617.15 | 275.70K |
| Sep 22 | $624.02 | $632.72 | $619.62 | $630.19 | 303.00K |
| Sep 21 | $614.12 | $627.04 | $613.10 | $624.20 | 188.20K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →